Bambusa Therapeutics Inc., a clinical stage biotechnology company, said it has dosed the first patient in its phase 1b clinical trial of a novel treatment for patients with COPD.
According to a company press release, the proof-of-concept study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BBT002 in COPD and other type 2 inflammatory respiratory conditions, such as asthma or chronic rhinosinusitis. Data from the trial are expected in the second half of 2026.
Type 2 inflammation underlies many allergic and inflammatory disorders ranging from atopic dermatitis in early childhood to COPD in later life. Despite this shared biology, Bambusa said current therapies are aimed at addressing individual disease manifestations rather than evolving along the spectrum of diseases as people age.
BBT002 is a first-in-class, half-life-extended antibody that is designed to simultaneously inhibit IL-4/IL-13 and IL-5 signaling, which are two central drivers of type 2 inflammation. The company said that by targeting both pathways in a single, long-acting molecule, it hopes BBT002 will deliver broader and more durable suppression of underlying disease biology than existing single-target therapies.
“COPD has seen remarkably limited therapeutic innovation over the past several decades,” said Shanshan Xu, MD, PhD, founder and CEO of Bambusa Therapeutics. “Moving BBT002 from healthy volunteers to proof-of-concept studies in just seven months demonstrates the power of our bispecific platform.”
